Open AccessDynamics of interleukin-17 in patients with multiple sclerosis and two-phase model of disease patho-genesis
Author(s) -
Т. В. Байдина,
N. V. Sursyakova,
Marina Danilova,
Т. Н. Трушникова,
Е. М. Куклина
Publication year - 2021
Publication title -
permskij medicinskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2687-1408
pISSN - 0136-1449
DOI - 10.17816/pmj38448-53
Subject(s) - medicine , multiple sclerosis , disease , cytokine , interleukin , interleukin 6 , gastroenterology , immunology
Objective. To study the concentration of the pro-inflammatory cytokine interleukin-17 in the blood serum of patients with multiple sclerosis.
Materials and methods. 68 patients with multiple sclerosis were examined. The severity of neurological deficit was assessed by EDSS and MSFC. The concentration of interleukin-17 in the blood serum was determined by the method of enzyme-linked immunosorbent assay.
Results. It was found that in patients with multiple sclerosis, the concentration of interleukin-17 in the blood serum, normal in the group as a whole, was induced by the effect of immunomodulatory therapy as well as the decrease in the activity of inflammatory processes with an increase in the duration of disease.
Conclusions. It was found that MDDMS therapy is most effective in the early stages of the disease; in the later stages, activities associated with neurotrophic support play a special role.